---
title: "Novo Nordisk: The 7.2mg semaglutide Phase 3 clinical trial achieved its primary endpoint, with a 20.7% weight loss over 72 weeks"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/225425727.md"
description: "On January 17th local time, Novo Nordisk announced the main results of the Phase 3b clinical trial STEP UP. In the STEP UP obesity trial, a weekly subcutaneous injection of 7.2mg semaglutide resulted in a weight loss of 20.7% at 72 weeks, with a weight loss of 18.7% regardless of treatment adherence. The trial achieved its primary endpoint, showing statistically significant and superior weight loss with 7.2mg semaglutide compared to placebo at week 72"
datetime: "2025-01-18T10:33:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/225425727.md)
  - [en](https://longbridge.com/en/news/225425727.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/225425727.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/225425727.md) | [繁體中文](https://longbridge.com/zh-HK/news/225425727.md)


# Novo Nordisk: The 7.2mg semaglutide Phase 3 clinical trial achieved its primary endpoint, with a 20.7% weight loss over 72 weeks

According to Jinshi Data on January 18, local time on January 17, Novo Nordisk announced the main results of the Phase 3 clinical trial STEP UP. In the STEP UP obesity trial, a weekly subcutaneous injection of 7.2mg semaglutide resulted in a weight loss of 20.7% at 72 weeks, with a weight loss of 18.7% regardless of treatment adherence. The trial achieved its primary endpoint, showing statistically significant and superior weight loss compared to placebo at week 72 with 7.2mg semaglutide

### 相关股票

- [Novo Nordisk AS (NVO.US)](https://longbridge.com/zh-CN/quote/NVO.US.md)
- [Eli Lilly (LLY.US)](https://longbridge.com/zh-CN/quote/LLY.US.md)

## 相关资讯与研究

- [Omeros Turns Corner With Novo Deal, YARTEMLEA Launch](https://longbridge.com/zh-CN/news/281666535.md)
- [As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?](https://longbridge.com/zh-CN/news/270794581.md)
- [SpaceX IPO: Will It Be a Buy or a Bust?](https://longbridge.com/zh-CN/news/281674034.md)
- [Orient Securities Keeps Their Buy Rating on Geely Automobile Holdings (GELYF)](https://longbridge.com/zh-CN/news/281674321.md)
- [What Is the Jevons Paradox and What Does It Mean for Micron and Sandisk Investors After Google's Revolutionary AI Breakthrough?](https://longbridge.com/zh-CN/news/281674984.md)